Compare Sunrun Inc (RUN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs Sanofi SA — how do they compare? Sunrun Inc trades at $10.1 (market cap $2.42B), while Sanofi SA trades at $43.52 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 43.1× Sunrun Inc's market cap, and Sanofi SA pays a 5.55% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| RUN | SNY | |
|---|---|---|
Market Cap | $2.42B | $104.30B |
Sector | Technology | Health |
52-Week High | $21.41 | $52.34 |
52-Week Low | $9.38 | $41.33 |
Enterprise Value | $16.93B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $10.19, up 3.24% today, but faces bearish technical signals despite strong earnings beats in recent quarters. The company shows solid valuation metrics with P/E of 6.82 and P/S of 0.78, though cash flow remains negative from operations. Recent news highlights mixed sentiment with Q2 earnings beating expectations but guidance cuts weighing on investor confidence.
The outlook remains cautious with analyst consensus bullish (62% buy ratings) and a $14.38 price target suggesting 41% upside potential. Key risks include negative operating cash flow, high debt levels, and competitive pressures in the solar industry. The stock offers value opportunity but requires careful monitoring of cash generation improvements.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
